Company
Every investor coverage indicates participated in a round Glyscend raised.
Investors whose own portfolio pages list Glyscend, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Glyscend acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Ashish Nimgaonkar | President & CEO | Brandon BioCatalyst portfolio (21 Sep 2022), Brandon BioCatalyst portfolio (12 May 2022) |
| Ashish Nimgaonkar, M.D. | President and Chief Executive Officer | Brandon Capital portfolio |
| Mark Fineman | Chief Development Officer | Brandon BioCatalyst portfolio |
| Mark Fineman, Ph.D. | Chief Development Officer | Brandon Capital portfolio |
| Professor Christopher Rayner | Principal Investigator of the Phase 1 Study | Brandon BioCatalyst portfolio |
Stories naming Glyscend. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.